BioMarin Pharma (BMRN) Posts Q4 Loss of $0.53
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.38 -1.93%
Revenue Growth %: +31.4%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
LTBR, AES, SYRS, More
Revenue Growth %: +31.4%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.53), which may not compare to the analyst estimate of ($0.38). Revenue for the quarter came in at $300 million versus the consensus estimate of $295.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loews Corp. (L) Reports Q3 EPS of $1.50
- Verra Mobility (VRRM) Tops Q3 EPS by 10c ; Offers Guidance
- Cboe Global Markets (CBOE) Tops Q3 EPS by 21c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
